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Introduction
Inflammatory bowel diseases (IBD) normally manifest in
adolescent and young adults; nevertheless, in about 1%
of the cases, disease onset occurs before the 1st year of
age. The clinical picture is often characterized by an
indeterminate colitis whose clinical remission is difficult
to achieve. Current treatment for IBD consists of either
immunosuppressant or biological (Infliximab, Adalimu-
mab) agents.
Case report
A girl born from non-consanguineous parents of Swiss,
Spanish and Korean origin, presented, at the age of 5
months, with bloody diarrhea, anal tags, vomiting, anor-
exia, mimicking a severe proctocolitis due to cow’s milk
protein allergy, non-responsive to elimination diet.
Infections, celiac disease, cystic fibrosis were also
excluded. Immunogical investigations, NBT, ANA,
ASCA and ANCA were negative, and immunoglobulins
were within the normal range.Due to persistent symp-
toms and failure to thrive, upper and lower endoscopiy
was performed showing an ulcerative ileo-pancolitis.
The histological analysis confirmed a focally erosive,
non-granulomatous ileo-colitis Leading to a differential
diagnosis of Crohn’s disease versus indeterminate colitis.
The patient clinically improvend with steroids and
azathioprine. The follow-up was marked by arthritis of
the ankle and knee, and erythema nodosum. She did not
present severe or recurrent infections, besides those
commonly associated with immunosuppresive therapy.
Digestive symptoms were first cortico-dependent and
eventually cortico-resistent, therefore, in alternative to
azathioprine, infliximab, adalimumab and methotrexate
were sequencially introduced. Despite these multiple
therapies, a sustained remission could not be achieved.
On the basis of the important systemic inflammation
associated to joint involvement, the patient was started
on tocilizumab, an anti-IL-6 receptor known for its effi-
cacy in sytemic-onset juvenile idiopathic arthritis. The
new treatment was well tolerated and induced a sub-
stantial improvement of the digestive and articular
symptoms, together with the laboratory parameters, over
6 months follow up.
Discussion
We report the efficacy of anti-IL-6R therapy in a child
affected by a severe early onset IBD, not responding to
traditional therapy. Recent works indicate a role of
IL-10 pathway in the pathogenesis of early onset colitis.





1Gastroenterology Unit, Department of Pediatrics, Centre Hospitalier
Universitaire Vaudois (CHUV), Lausanne, Switzerland. 2Immunology,
Allergology and Rheumatology Unit, Department of Pediatrics, Centre
Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Published: 8 November 2013
References
1. Kotlarz D, et al: Loss of interleukin-10 signaling and infantile
inflammatory bowel disease: implications for diagnosis and therapy.
Gastroenterology 2012, 143(2):347-55.
2. Smolen JS, et al: Consensus statement on blocking the effects of
interleukin-6 and in particular by interleukin-6 receptor inhibition in
rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis
2013, 72(4):482-92.
doi:10.1186/1546-0096-11-S1-A222
Cite this article as: Helbling et al.: P03-024 – Early onset IBD treated by
tocilizumab. Pediatric Rheumatology 2013 11(Suppl 1):A222.
2Immunology, Allergology and Rheumatology Unit, Department of Pediatrics,
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
Full list of author information is available at the end of the article
Helbling et al. Pediatric Rheumatology 2013, 11(Suppl 1):A222
http://www.ped-rheum.com/content/11/S1/A222
© 2013 Helbling et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
